Eleuthero for Health & Longevity - Quick Reference Sheet

Eleuthero for Health & Longevity

Created on 09/20/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Eleuthero is the root of a Far Eastern shrub, sold for stress and fatigue. Only one controlled trial gave a clear result on a general health questionnaire, and that gain faded with continued use. Endurance, immune, mood and fatigue claims conflict or come from multi-herb formulas. Side effects match placebo; the worst harm traced to a substituted plant. (Full Review)

Protocol

Standard dose
300–1,200 mg daily
Dry root extract, the range used in modern trials. Dried root alternative: 2–4 g daily.
Best time of day
Morning
Last dose before 14:00, split between morning and midday. No trial has dosed it in the evening.
Standardisation target
Eleutheroside B + E ≈ 0.8%
Products without a declared marker content cannot be compared to any trial dose.
Time to effect
Social functioning
4 weeks
The advantage present at four weeks had faded by eight.
Endurance capacity
8 weeks
Duration of the single positive trial of peak oxygen uptake and time to exhaustion.
Memory and recall
12 weeks
Figure recall improved over twelve weeks, in a trial of eleuthero leaf given with a second herb.

Benefits

Contraindications
  • Uncontrolled hypertension (sustained ≥ 160/100 mmHg)
  • Bipolar disorder during a manic or mixed episode
  • Solid-organ transplant recipients on calcineurin inhibitors; autoimmune disease on active immunosuppressive therapy
  • Hormone-sensitive cancers under active endocrine therapy
  • Digoxin therapy without access to serum-level monitoring
  • Pregnancy and lactation
  • Children under 12 years
  • Surgery scheduled within the next 14 days
Key Interactions
  • Digoxin
  • Antidiabetic medications (insulin, metformin)
  • Antihypertensive medications (lisinopril, losartan)
  • Anticoagulants and antiplatelets (warfarin, apixaban)
  • Sedatives and central nervous system depressants (zolpidem, alprazolam)
  • Serotonergic antidepressants (duloxetine, paroxetine, sertraline) and agomelatine
  • Lithium
  • Over-the-counter stimulants (caffeine tablets, pseudoephedrine decongestants)
  • Over-the-counter sedating sleep aids (diphenhydramine, doxylamine)
  • Other adaptogenic supplements (Rhodiola rosea, Panax ginseng, Withania somnifera)
  • Blood-sugar-lowering supplements (berberine, chromium)
  • Blood-pressure-lowering supplements (beetroot nitrate, potassium)
  • Immune-stimulating supplements (Echinacea purpurea, beta-glucans, Astragalus membranaceus)
  • Melatonin and evening sleep protocols
  • Heat exposure and high-intensity training blocks

Risk & Side Effects

  • Medium: Gastrointestinal upset, skin rash and headache
  • Low: Insomnia, irritability and overstimulation; raised serum digoxin concentration; blood pressure changes in treated hypertension; blood glucose disturbance; bleeding events on platelet-active co-medication; harm from species substitution in products sold as eleuthero
  • Speculative: Lowered testosterone-to-cortisol ratio under heavy training load; stimulation of hormone-sensitive tissue

Monitoring

Marker Target Why
Blood pressure 110–125 / 70–80 mmHg Detects either direction of the disputed pressure effect
Fasting blood glucose 75–86 mg/dL Catches additive glucose lowering with diabetes medication
Glycated haemoglobin 4.8–5.3% Tracks average glucose independent of a single day's reading
High-sensitivity C-reactive protein Under 0.5 mg/L Tests the claimed anti-inflammatory action
Morning serum cortisol 10–15 µg/dL drawn at 08:00 The stress-axis target of the whole adaptogen claim
DHEA-sulfate No established target; upper third of age/sex range Interpreted alongside cortisol to judge adrenal balance
Total testosterone, men in heavy training 600–900 ng/dL Detects the testosterone-to-cortisol shift seen in athletes
Alanine and aspartate aminotransferase 10–26 U/L Confirms no liver injury from a substituted or contaminated product
Serum digoxin, only if taking digoxin 0.5–0.9 ng/mL The one documented drug interaction
Fasting lipid panel Triglycerides under 80 mg/dL; high-density lipoprotein cholesterol above 55 mg/dL Tracks the lipid changes reported in the open study

Cadence: Baseline before the first dose. Home blood pressure twice weekly for the first four weeks, then monthly; glucose, liver enzymes and the morning stress-hormone panel at 8 weeks and again at 6 months, then every 6–12 months. Serum digoxin at 2–4 weeks after starting and again after stopping.

Qualitative Assessment

  • Sleep onset time and number of night wakings
  • Perceived energy through the mid-afternoon
  • Tolerance of training load and recovery between hard sessions
  • Mental clarity and ability to sustain attention
  • Irritability, restlessness and jitteriness
  • Frequency and duration of respiratory infections